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ABBREVIATIONS  28 
ATIS – Adipose tissue insulin sensitivity 29 
BAM – Black (west) African men 30 
WEM – White European men 31 
Rd – Rate of disappearance 32 
Ra – Rate of appearance 33 
VAT – Visceral adipose tissue 34 
SAT – Subcutaneous adipose tissue 35 
IMCL – Intramyocellular lipids 36 
IHL – Intrahepatic lipids 37 
MRI – Magnetic resonance imaging 38 
MRS – Magnetic resonance spectroscopy   39 
HISI – Hepatic insulin sensitivity index 40 
PISI – Peripheral insulin sensitivity index  41 
BMI – Body mass index  42 




Objectives: In men of black west African (BAM) and white European (WEM) ethnicity, we 45 
aimed to 1) compare adipose tissue, peripheral and hepatic insulin sensitivity, and 2) investigate 46 
associations between ectopic fat and insulin sensitivity by ethnicity. 47 
Design and Methods: In overweight BAM (n=21) and WEM (n=23) with normal glucose 48 
tolerance, we performed a two-step hyperinsulinaemic–euglycaemic clamp with infusion of 49 
[6,6 2H2]-glucose and [
2H5]-glycerol to measure whole body, peripheral, hepatic and adipose 50 
tissue insulin sensitivity (lipolysis). Visceral adipose tissue (VAT), intrahepatic lipids (IHL) 51 
and intramyocellular (IMCL) lipids were measured using magnetic resonance imaging and 52 
spectroscopy. Associations between insulin sensitivity and ectopic fat were assessed using 53 
Pearson’s correlation coefficient by ethnicity and regression analysis. 54 
Results: There were no ethnic differences in whole body or tissue-specific insulin sensitivity 55 
(all p>0.05). Suppression of lipolysis was inversely associated with VAT and IHL in WEM but 56 
not BAM (VAT: WEM r=-0.68, p<0.01; BAM r=0.07, p=0.79. IHL: WEM r=-0.52, p=0.01; 57 
BAM r=-0.12, p=0.63). IMCL was inversely associated with skeletal muscle insulin sensitivity 58 
in WEM but not BAM (WEM r=-0.56,p<0.01; BAM r=-0.09, p=0.75) and IHL was inversely 59 
associated with hepatic insulin sensitivity in WEM but not BAM (WEM r=-0.53, p=0.02; BAM 60 
r=-0.13, p=0.62). 61 
Conclusions: Ectopic fat deposition may play a lesser role in reducing insulin sensitivity in 62 
men of black African ethnicity, and may not be driven by lipolysis. Resistance to storing VAT, 63 
IHL and IMCL may enable men of black African ethnicity to maintain comparable insulin 64 
sensitivity to white Europeans.  65 
 66 
Keywords: Black African, Hepatic insulin sensitivity, Intrahepatic lipid, Intramyocellular 67 




The risk of developing type 2 diabetes (T2D) is disproportionately high in populations of black 70 
compared to white ethnicity (1, 2). In black populations, T2D is more likely to occur within 71 
the normal body mass index (BMI) range (19.5-24.9 kg/m2) (3) and at a lower waist 72 
circumference (4) compared to white groups.  73 
 74 
Insulin resistance for carbohydrate metabolism is a well-established early defect in the 75 
pathogenesis of T2D (5). Resistance to the antilipolytic effect of insulin in adipose tissue has 76 
also been identified as an early defect, occurring prior to the onset of hyperglycaemia (6). 77 
Adipose tissue insulin resistance results in increased fatty acid release, with deposition in non-78 
adipose tissue sites as ectopic fat (7, 8). This is known to trigger and exacerbate insulin 79 
resistance (9). Several theories have been proposed to explain the development of ectopic fat 80 
and insulin resistance. The “spillover theory” proposes that multiple dysfunctions of 81 
subcutaneous adipose tissue (SAT), including insulin resistance (10), allow fatty acids to be 82 
deposited as visceral adipose tissue (VAT) (7, 11). Dysfunctional SAT combined with highly 83 
lipolytic VAT leads to the release of fatty acids into the portal and peripheral circulations. The 84 
“portal theory” proposes that delivery of fatty acids from VAT to the liver, via the portal 85 
circulation, results in accumulation of intrahepatic lipid (IHL), which subsequently leads to the 86 
development of hepatic insulin resistance (12-14). Fatty acids entering the peripheral 87 
circulation are understood to lead to fat deposition within skeletal muscle cells (termed 88 
intramyocellular lipids, IMCL) (13, 15). Whilst there is compelling evidence linking IMCL 89 
with peripheral insulin resistance (16, 17), there is debate in this field due to observations that 90 




Compared to populations of white ethnicity, black populations are reported to exhibit lower 93 
ectopic fat (namely VAT and IHL) (19-23), yet large cohort studies indicate that they display 94 
pronounced insulin resistance (24), creating a paradox. Studies using more sensitive measures 95 
of insulin resistance at a tissue specific level, alongside measurement of ectopic fat depots 96 
related to T2D are scarce in non-diabetic black populations and have been restricted to obese 97 
women (25). These have reported no ethnic differences in peripheral insulin sensitivity, but 98 
lower hepatic insulin sensitivity in white compared to black women. Furthermore, they report 99 
that peripheral insulin sensitivity does not associate with either VAT or IMCL in black women 100 
but hepatic sensitivity does associate with VAT and IHL, suggesting that VAT and IHL play a 101 
key role in hepatic insulin resistance in black women (25).  Similarly, in vivo studies assessing 102 
adipose tissue insulin sensitivity are mainly confined to obese women. They have provided 103 
inconsistent results, showing either no difference (26-28) or reduced lipolysis (29-31) in black 104 
compared to white populations.  105 
 106 
While studies in women provide persuasive evidence of ethnic distinctions in the 107 
pathophysiology of T2D, gender differences in physiology (greater hyperinsulinaemia and 108 
insulin resistance in women (32, 33)) and body composition (less VAT and more SAT in 109 
women (34)) suggest investigations in black men are required. We aimed to assess and compare 110 
whole body, skeletal muscle, hepatic and adipose tissue insulin sensitivity in normally glucose 111 
tolerant black west African (BAM) and white European men (WEM), and to evaluate 112 
relationships between tissue specific insulin sensitivity with VAT, IHL and IMCL, to explore 113 
ethnic distinctions in the pathophysiology of type 2 diabetes.     114 
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MATERIALS AND METHODS 115 
Participants 116 
The participants included in this analysis were recruited as part of the South London Diabetes 117 
and Ethnicity Phenotyping (Soul-Deep) study, phase II (35). The aim of the Soul-Deep II study 118 
was to investigate ethnic differences in insulin sensitivity, beta-cell function and ectopic fat 119 
deposition in men of Black (west) African (BAM) and white European (WEM) ethnicity. The 120 
study was approved by the London Bridge National Research Ethics Committee (15/LO/1121). 121 
Data collection took place between April 2016 and May 2018. Participants were recruited from 122 
local GP practices, newspaper advertisements, King’s College London university staff and 123 
student email, religious groups, leafleting and posters where permitted. All participants 124 
provided informed consent prior to any study procedures.  125 
Non-diabetic Black (west) African (BAM) and white European men (WEM) aged 18-65 years, 126 
with a BMI between 20-40 kg/m2 were eligible to take part; the aim of recruitment was to 127 
achieve comparable BMI and age between the ethnic groups, without targeting a specific 128 
weight status. Ethnicity was defined by self-reported parental and grandparental birthplace; 129 
normal glucose tolerance was confirmed by a 2-hour plasma glucose <7.8mmol/l following a 130 
75g oral glucose tolerance test at screening. Participants were excluded if they were being 131 
treated with any medications known to affect the study outcomes, suffering from kidney or 132 
liver damage (serum creatinine >150 μmol/l or serum alanine transaminase level >2.5-fold 133 
above the upper limit of the reference range), or were unwilling and/or unable to comply with 134 
the study protocol.  135 
Prior to each visit, participants were required not to eat after their usual carbohydrate-136 
containing evening meal (no less than 10 hours prior to study), refrain from strenuous physical 137 
activity for 48 hours and alcohol for 24 hours and avoid smoking on the morning of their visit.  138 
Hyperinsulinaemic–euglycaemic clamp 139 
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A two-step hyperinsulinaemic–euglycaemic clamp with a stable glucose and glycerol isotope 140 
infusion was used to assess whole body and tissue specific insulin sensitivity. Upon arrival at 141 
the clinical research facility in King’s College Hospital, participants were advised to empty 142 
their bladder and were weighed on a body composition analyser (Tanita MC780MA) to 143 
determine fat free mass and body weight for infusion calculations. A cannula for blood 144 
sampling was placed in the dorsum of one hand in a retrograde fashion, the hand was kept in a 145 
warming unit at 55º to mimic arterialised sampling. Duplicate baseline samples were taken to 146 
assess background glucose and glycerol isotopic enrichments. An infusion cannula was then 147 
inserted into an antecubital fossa vein on the adjacent arm for infusions of 20% (wt/vol) 148 
glucose, insulin (Actrapid, Novo Nordisk, Bagsvaerd, Denmark) bound to albumin in a 4% 149 
autologous blood/saline solution, [6,6-2H2]-glucose and [
2H5]-glycerol tracers (CK Gases, 150 
Cambridgeshire, UK). To begin the basal phase, a primed (2.0 mg/kg), continuous infusion 151 
(0.02 mg/kg−1 min−1) of [6,6-2H2]-glucose and a primed (0.12 mg/kg), continuous infusion 152 
(0.0067 mg/kg−1 min−1) of [2H5]-glycerol were initiated at -120 minutes (36). Blood samples 153 
were taken at -30, -20, -10 and 0 minutes for basal assessments. The clamp began at 0 minutes 154 
with a primed continuous insulin infusion at a rate of 10 mU m−2 BSA min−1 (low dose insulin 155 
phase) for 2 hours for assessment of adipose tissue and hepatic insulin sensitivity. For the final 156 
2 hours, the [2H5]-glycerol isotope infusion was terminated, the insulin infusion rate was re-157 
primed and increased to 40 mU m−2 BSA min−1 (the high dose insulin phase) for assessment of 158 
whole body and peripheral (skeletal muscle) insulin sensitivity (37, 38). Euglycaemia (5 159 
mmol/l) was achieved using 20% glucose enriched with [6,6-2H2]-glucose (8 mg/g glucose 160 
with low-dose insulin and 10 mg/g with high-dose insulin) to maintain a constant tracer-to-161 
tracee ratio. The glucose was given at variable rates, based on plasma glucose samples drawn 162 
every 5 minutes and measured on a bedside glucose analyser (Yellow Spring Instruments, 2300 163 
STAT Glucose Analyzer, Yellow Springs, OH, USA). Blood was drawn at 30, 60, 90, 100, 164 
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110, 120, 150, 180, 210, 220, 230 and 240 minutes for the assessment of plasma glucose 165 
concentration and isotopic enrichment and insulin concentration (38).   166 
Magnetic resonance imaging and spectroscopy for ectopic fat quantification  167 
Magnetic resonance imaging (MRI) was used assess visceral adipose tissue (VAT) and 168 
intrahepatic lipids (IHL). Proton-magnetic resonance spectroscopy (1H-MRS) was used to 169 
assess intramyocellular lipids (IMCL). Full details of this methodology can be found in (39). 170 
In brief, participants arrived at the MRI unit of Guy’s Hospital, London following an overnight 171 
fast. Participants were scanned in a 1.5T Siemens Aera scanner, axial 2-point Dixon MRI 172 
images were acquired from the abdomen, from which fat and water images were produced. 173 
Images were analysed using imaging software (HOROS V 1.1.7; www.horosproject.org; 174 
accessed 21/10/2017) to quantify VAT and IHL. VAT area was assessed using a single slice at 175 
the L4-5 spinal anatomical position. IHL was quantified using 2 abdominal MRI images 30 176 
mm apart encompassing both the superior and inferior view of the liver. A 4-circular region of 177 
interest analysis was conducted to determine the hepatic fat fraction (%) in each region. IHL 178 
was calculated as the mean of all 8 regions of interest. Quantification of IMCL in the soleus 179 
muscle of the right leg was derived from a 1H-MRS scan on a 1.5T Siemens system with an 180 
extremity RF coil to obtain muscle images. From these images two localised proton spectra 181 
were obtained, a water-suppressed lipid spectra and a lipid-suppressed water spectra. The Java-182 
Based Magnetic Resonance User Interface software was used to identify and quantify the 183 
IMCL peaks expressed in arbitrary units (40). 184 
Laboratory analysis 185 
Plasma glucose and glycerol isotope enrichments were measured by gas chromatography-mass 186 
spectrometry on an Agilent GCMS 5975C MSD (Agilent Technologies, Wokingham, UK) 187 
using selected ion monitoring to determine the tracer-to-tracee ratio. The isotopic enrichment 188 
of glucose was determined as the penta-O-trimethylsilyl-D-glucose-O-methoxime derivative 189 
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(41). The isotopic enrichment of plasma glycerol was determined as the tert-butyl trimethylsilyl 190 
(tBDMS) glycerol derivative (42). Plasma insulin concentration was measured by 191 
immunoassay using chemiluminescent technology (ADVIA Centaur System, Siemens 192 
Healthcare, Camberley, UK).  193 
Calculations 194 
Whole body insulin sensitivity was quantified using the M value (mg/kg FFM min-1) measured 195 
during the final 30 minutes of the high dose insulin phase of the clamp. It is calculated as total 196 
glucose disposal corrected for deviations in plasma glucose concentration. The M value was 197 
divided by mean plasma insulin concentration during the high dose insulin phase, giving M/I 198 
(mg kg FFM min-1) / (pmol/l) as another assessment of whole body insulin sensitivity (37). 199 
Steele’s non-steady-state equations modified for stable isotopes (43) were used to determine 200 
peripheral glucose utilisation (glucose rate of disappearance, Rd (μmol /kg FFM min-1)), 201 
endogenous glucose production (glucose rate of appearance, Ra (μmol /kg FFM min-1)) and 202 
whole body lipolysis (glycerol Ra (μmol /kg FFM min-1) ) at basal and during the different 203 
phases of the clamp. Glucose kinetic calculations were modified to incorporate the [6,6-2H2]-204 
glucose isotope enriched 20% glucose (44). Optical segment analysis was used to smooth the 205 
glucose and glycerol enrichment concentrations over the clamp time course (45). 206 
Peripheral insulin sensitivity was determined as the percentage increase in the rate of glucose 207 
disappearance from basal to the final 30 minutes of the high dose insulin phase. The peripheral 208 
insulin sensitivity index (PISI) was also calculated as the glucose Rd (μmol /kg FFM min-1) / 209 
mean plasma insulin concentration (pmol/l) during the final 30 minutes of the high dose insulin 210 
phase (46). Peripheral insulin sensitivity is predominantly driven by skeletal muscle glucose 211 
uptake but also captures adipose tissue glucose uptake hence, we have used PISI as an 212 
assessment of skeletal muscle insulin sensitivity.  213 
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Endogenous glucose production (glucose Ra) was calculated by subtracting the exogenous 214 
glucose infusion rate from total glucose Ra. Hepatic insulin sensitivity was measured as the 215 
percentage suppression of endogenous glucose production from basal to the final 30 minutes 216 
of the low dose insulin phase (47). Hepatic insulin sensitivity was also quantified during the 217 
basal and low dose insulin phase using the hepatic insulin sensitivity index (HISI), which is the 218 
reciprocal of the product of endogenous glucose production (glucose Ra) and mean plasma 219 
insulin (46).  220 
Adipose tissue insulin sensitivity was measured as the percentage suppression of whole body 221 
lipolysis (glycerol Ra) from basal to the final 30 minutes of the low dose insulin phase (47). 222 
Adipose tissue insulin sensitivity was also quantified during the basal and low dose insulin 223 
phase using the adipose tissue insulin sensitivity index (ATIS) which is the reciprocal of the 224 
product of whole body lipolysis (glycerol Ra) and basal plasma insulin (46). 225 
Statistical analysis 226 
The Soul-Deep II study was powered on a primary outcome of insulin secretory function (48). 227 
Allowing a difference of one standard deviation to be detected with 90% power and 2-sided 228 
significance, we aimed to recruit 23 per group, allowing for 20 per group to complete the 229 
protocol. 230 
Data were assessed for normality using the Shapiro-Wilks test and histograms. A log 10 231 
transformation was performed where data were skewed. Data which were normally distributed 232 
are presented as mean (SD), data which required log 10 transformation are presented as 233 
geometric mean (95% CI), data which remained skewed after log transformation are presented 234 
as median (lower-upper IQR). Ethnic comparisons of insulin sensitivity were assessed using 235 
the independent samples t-test for normally distributed data and Mann-Whitney test for non-236 
normally distributed data. The mean difference (95% CI) and ratio of the geometric mean (95% 237 
CI) are presented where appropriate. Adjustment of the insulin sensitivity measures for VAT 238 
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and IHL were made using linear multiple regression. Pearson’s correlation analyses were used 239 
to assess the associations between insulin sensitivity measures and ectopic fat. Interaction by 240 
ethnicity was assessed using a linear multiple regression with ethnicity*ectopic fat depot used 241 
as the interaction term. Statistical significance was defined as p <0.05 and data analyses were 242 




Participant characteristics 245 
The participant characteristics of the 21 BAM and 23 WEM are displayed in Table 1; by design 246 
the groups were comparable in age and BMI. There were no differences in body fat, waist 247 
circumference, blood pressure, HbA1c, cholesterol, fasting and post-load glucose between 248 
ethnicities; however, BAM exhibited lower fasting triglycerides compared to WEM. Data on 249 
ectopic fat depots in these volunteers, as previously reported by our group (39), showed lower 250 
VAT and IHL in BAM but similar IMCL (included in Table 1 for reference). 251 
Whole body insulin sensitivity 252 
The glucose and insulin profiles during the hyperinsulinaemic–euglycaemic clamp are shown 253 
in Supplementary Figure 1. BAM exhibited a trend towards greater mean plasma insulin during 254 
the high dose insulin phase (ratio of the geometric mean and 95% CI of 1.10 (1.00, 1.21), 255 
p=0.05). There were no ethnic differences in whole body insulin sensitivity, measured as either 256 
M value (BAM: 9.65 (2.32) vs WEM: 9.51 (3.86) mg/kg FFM min-1, p=0.89) or M/I (BAM: 257 
0.0171 (0.0059) vs WEM: 0.0189 (0.0094) ((mg/kg FFM min-1) / (pmol/l)), p=0.44). 258 
Associations between VAT, IHL and IMCL with whole body insulin sensitivity (measured as 259 
either M value or M/I) are shown in Supplementary Table 1. When combining all participants 260 
as a single cohort, there were significant inverse associations between VAT, IHL, and IMCL 261 
with whole body insulin sensitivity; however, when assessing the ethnic groups separately, 262 
these relationships were significant in WEM but weaker or absent in BAM.  263 
Adipose tissue insulin sensitivity 264 
Adipose tissue insulin sensitivity (ATIS) index did not differ by ethnicity during the basal or 265 
insulin stimulated state (Table 2). Insulin mediated suppression of glycerol was used as a 266 
measure of adipose tissue insulin sensitivity to lipolysis and was not significantly different by 267 
ethnicity (mean difference (95% CI) -8.55 (-22.0, 4.90) %, p=0.21), Supplementary Figure 2A. 268 
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There was a trend towards lower adipose tissue insulin sensitivity to lipolysis when adjusting 269 
for VAT in BAM (adjusted mean difference (95% CI) -12.4 (-26.9, 2.21) %, p=0.09). Across 270 
the whole cohort, adipose tissue insulin sensitivity did not correlate with VAT, IHL or IMCL 271 
(Figure 1A-C). However, when assessing WEM and BAM separately, adipose tissue insulin 272 
sensitivity to lipolysis correlated with VAT and IHL in WEM but there were no significant 273 
correlations in BAM (Figure 1A & B). When modelled with suppression of lipolysis, ethnicity 274 
had no significant interaction with VAT (p=0.12) or IHL (p=0.58). There were no significant 275 
correlations between the suppression of lipolysis and IMCL in either ethnic group (Figure 1C).  276 
Peripheral insulin sensitivity  277 
We found no ethnic differences in peripheral insulin sensitivity, measured as percentage 278 
increase in glucose utilisation from the basal to high dose insulin phase of the clamp (BAM 279 
304.82 (111.11) vs WEM 286.24 (138.44) %, p =0.63), Supplementary Figure 2B. There was 280 
also no ethnic difference when accounting for the insulin concentration during the high dose 281 
insulin phase, using PISI (mean difference (95% CI) -1.06 x10-2 (-3.87 x10-2 ,1.74 x10-2 ) (μmol 282 
/kg FFM min-1 )/ pmol/l, p=0.43), Table 2. Adjusting PISI for VAT (which we have previously 283 
reported as lower in BAM), resulted in significantly lower PISI in BAM (adjusted mean 284 
difference (95% CI) -3.47 x10-2 (-5.67 x10-2 , -1.27 x10-2 ) (μmol /kg FFM min-1 )/ pmol/l, 285 
p<0.01). Across the whole cohort, PISI correlated significantly with VAT and IMCL (Figure 286 
1D-E). When assessing WEM and BAM separately, PISI correlated significantly with VAT 287 
and IMCL in WEM; however, in BAM the association with VAT was weaker (Figure 1D) and 288 
there was no association with IMCL (Figure 1E). When modelled with PISI, interactions 289 
between ethnicity and VAT and between ethnicity and IMCL were not significant (p=0.11 and 290 
p=0.11, respectively).  291 
Hepatic insulin sensitivity  292 
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We found no ethnic differences in the basal or insulin stimulated hepatic insulin sensitivity 293 
index (HISI), Table 2. Using suppression of endogenous glucose production as a measure of 294 
hepatic insulin sensitivity, we found no evidence for an ethnic difference (mean difference 295 
(95% CI) -4.15 (-14.83, 6.53) %, p =0.21), Supplementary Figure 2C. Adjusting hepatic insulin 296 
sensitivity for VAT, resulted in lower mean hepatic insulin sensitivity in BAM (mean 297 
difference (95% CI) -10.9 (-21.2, -0.72) %, p=0.04). Adjusting hepatic insulin sensitivity for 298 
IHL (which we have previously reported as lower in BAM), resulted in no ethnic difference in 299 
hepatic insulin sensitivity (adjusted mean difference (95% CI) -7.33 (-17.9, 3.24) %, p=0.17). 300 
Across the whole cohort, hepatic insulin sensitivity correlated with VAT and IHL (Figure 1F-301 
G). When assessing WEM and BAM separately, hepatic insulin sensitivity correlated 302 
significantly with VAT in both ethnicities (Figure 1F); however, the correlation with IHL was 303 
only significant in WEM (Figure 1G). When modelled with suppression of endogenous glucose 304 
production, interactions between ethnicity and VAT and between ethnicity and IHL were not 305 




In this study we have shown that whilst BAM and WEM display comparable whole body, 308 
skeletal muscle, hepatic and adipose tissue insulin sensitivity, the relationships between insulin 309 
sensitivity and ectopic fat are ethnically distinct.  310 
 311 
Resistance of adipose tissue to the antilipolytic effect of insulin is suggested to be a primary 312 
abnormality in the pathophysiology of T2D that occurs before the onset of hyperglycaemia (6). 313 
It has been proposed that VAT and ectopic fat accumulate as result of dysfunctional lipolysis, 314 
which allows an increase in circulating fatty acids, and other adipocyte abnormalities, 315 
described in the “spillover theory” (10, 49). Our study, which is the first to compare men of 316 
black African and white European ethnicity, shows that there are no associations between 317 
lipolysis and VAT, IHL or IMCL in BAM. Our findings agree with Albu et al. who showed a 318 
relationship between suppression of lipolysis and VAT in obese white women but not in black 319 
women (31). Together, these findings suggest lipolysis may not be driving the accumulation of 320 
ectopic fat in black people of either gender, suggesting the “spillover theory” may not hold true 321 
in this ethnic group.  322 
 323 
Visceral fat, IHL and IMCL play an integral role in the development of insulin resistance and 324 
T2D (12, 16, 17); however, black populations are consistently reported to exhibit lower levels 325 
of VAT (19-23) despite their high T2D risk. Our finding of lower VAT in BAM is in agreement 326 
with the literature. Despite this, we found comparable levels of insulin sensitivity. We 327 
investigated associations between VAT and insulin sensitivity and found that both peripheral 328 
and hepatic insulin sensitivity were significantly associated with VAT in both ethnicities. This 329 
leads us to believe that VAT is detrimental to skeletal muscle and hepatic insulin sensitivity in 330 
both ethnic groups, but that this impact occurs at lower VAT levels in BAM compared to WEM, 331 
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a so-called lower threshold. Our finding of a significant association between VAT and hepatic 332 
insulin sensitivity is consistent with earlier work in obese black women (25), however, our data 333 
in healthy men also show an association between VAT and skeletal muscle insulin sensitivity 334 
which has not been found in women (25, 50). This conflicting result may be due to the 335 
aforementioned studies focusing on women with severe obesity whilst our participants were 336 
only mildly overweight, or gender itself may explain the conflicting results, adding to the 337 
evidence for gender differences in T2D pathophysiology (33).  338 
 339 
Accumulation of IHL is proposed to be central to the development of hepatic insulin resistance. 340 
The “portal theory” describes the accumulation of IHL, which develops from the flux of fatty 341 
acids from VAT to the liver, via the portal vein. It is, therefore, not surprising that we found 342 
lower IHL in BAM, given the lower levels of VAT that they exhibited. Whilst our data from 343 
WEM corroborates the current understanding of T2D pathophysiology such that hepatic insulin 344 
sensitivity was significantly associated with IHL (14), we found no evidence for this 345 
relationship in BAM. This contrasts with data from studies in black women whereby IHL is 346 
associated with hepatic sensitivity (25, 26). This may point to IHL being more harmful in black 347 
women than men, although the obesity status of the women may also have contributed to this 348 
result (33).  349 
 350 
Intramuscular lipids, which accumulate as a result of skeletal muscle cells taking up fatty acids 351 
from the peripheral circulation, have been shown to be correlated with skeletal muscle insulin 352 
resistance (15). Whilst we saw a significant relationship between IMCL and skeletal muscle 353 
insulin sensitivity in WEM, this relationship was not present in BAM. This finding agrees with 354 
other studies (51-53), and suggests that skeletal muscle insulin resistance develops 355 




In contrast to the extensive evidence base that reports pronounced insulin resistance in 358 
populations of black African ethnicity (24, 54), we showed no ethnic differences in insulin 359 
sensitivity at a whole body and tissue specific level. The contrast in these findings are likely 360 
due to the different methodologies used to measure insulin sensitivity. In our study we have 361 
used the clamp method, which is a direct assessment of insulin sensitivity (37), while other 362 
methods estimate insulin sensitivity through indirect modelling. The use of such methods in 363 
black populations has been criticised because of the reduced insulin clearance and higher 364 
insulin levels that they exhibit, which may lead to an underestimation of modelled insulin 365 
sensitivity. Indeed, in an ethnic comparison of direct and indirect measures of insulin 366 
sensitivity, Pisprasert et al. showed no difference in insulin sensitivity using the clamp, while 367 
surrogate indices showed greater insulin resistance in African-Americans compared to white 368 
Americans. These data suggest caution should be applied when using indirect assessments of 369 
insulin resistance in black populations (55). Our findings are supported by several metabolic 370 
studies using glucose clamps and isotopes, which have also found comparable insulin 371 
sensitivity in healthy black and white communities (25, 26, 55-57). Our experimental design 372 
also limited potential confounding factors; participants were similar in BMI, participants with 373 
impaired glucose tolerance were excluded and our data collection included only men. 374 
 375 
We have previously published a description of the ectopic fat status for the current set of 376 
participants (39) in which we found no ethnic differences in IMCL, but significantly lower 377 
VAT and IHL in BAM. In the current study we adjusted our insulin sensitivity data for VAT 378 
and found lower whole body, skeletal muscle and hepatic insulin sensitivity in BAM. The 379 
reduced insulin sensitivity following adjustment for VAT, and the lower VAT storage in the 380 
presence of similar lipolysis, suggests that the detrimental effects of VAT occur at lower levels 381 
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in BAM and a resistance to storing VAT allows BAM to maintain comparable insulin 382 
sensitivity to WEM. In comparison, adjusting for IHL did not explain the similar hepatic insulin 383 
sensitivity and provides more evidence for an independent relationship between IHL and 384 
hepatic insulin sensitivity in BAM. Lower ectopic fat storage, despite similar lipolysis, may 385 
point to an increased tendency towards fat oxidation over ectopic storage in BAM; further 386 
studies assessing fatty acid oxidation are needed to explore this possibility.  387 
 388 
Although one of the strengths of this study was the use of rigorous measurements of insulin 389 
sensitivity and ectopic fat, we recognise that our conclusions for the associations between 390 
insulin sensitivity and ectopic fat may be limited by our sample size. While our sample size is 391 
comparable to other studies of this nature, it does affect the statistical adjustment for VAT/IHL 392 
and interaction analysis. Our insulin sensitivity data are based on lean mass assessed by 393 
bioimpedance methodology; this uses calculations which are not ethnically sensitive and could 394 
potentially lead to underestimation of lean mass and thus overestimating insulin sensitivity in 395 
BAM (58). Finally, although the aim of our recruitment was to achieve comparable BMIs in 396 
our groups, this resulted in a tendency towards lower waist circumferences in BAM, which 397 
may have also contributed to differences in the metabolic characteristics that we studied. A 398 
study in which the groups are matched for waist circumference would help to elucidate these 399 
effects. 400 
 401 
In summary, our data suggest that increased lipolysis due to adipose tissue insulin resistance 402 
may not be driving ectopic fat deposition in BAM. Additionally, ectopic fat accumulation in 403 
the liver and skeletal muscle may play less of a role in reducing insulin sensitivity in BAM 404 
compared to WEM. We provide evidence that the detrimental effects of VAT on glucose uptake 405 
and the suppression of endogenous glucose production occur at a lower VAT level in BAM. 406 
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We conclude that current theories regarding the accumulation of ectopic fat and its impact on 407 
insulin sensitivity may not apply in BAM, who display a resistance to storing visceral and 408 
hepatic fat. Future work, assessing the impact of ectopic fat on insulin secretory function, is 409 
vital before excluding ectopic fat as the culprit behind the increased prevalence of T2D in black 410 
populations.  411 
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Age (years) a 25 (22 – 40) 29 (25 – 53) 0.18 
BMI (kg/m2) 26.8 (3.6) 26.5 (4.5) 0.82 
Waist Circumference (cm) b 87.5 (83.4, 91.8) 92.8 (87.1, 99.0) 0.13 
Systolic BP (mm/Hg) 124.0 (11.9) 121.9 (9.1) 0.52 
Diastolic BP (mm/Hg) b 70.3 (65.5, 75.5) 70.7 (67.2, 74.3) 0.91 
Total Cholesterol (mmol/l) b 4.26 (3.85, 4.73) 4.65 (4.23, 5.11) 0.20 
LDL (mmol/l) 2.73 (0.84) 2.99 (0.82) 0.33 
HDL (mmol/l) a 1.2 (1.2 – 1.4) 1.2 (1.1 – 1.4) 0.86 
Triglycerides (mmol/l) b 0.67 (0.59, 0.77) 0.99 (0.81, 1.21) <0.01 
Fasting glucose (mmol/l) 5.1 (0.5) 5.2 (0.4) 0.55 
2-hour post load glucose (mmol/l) 5.28 (1.13) 5.09 (1.26) 0.61 
Ectopic fat depots    
Visceral adipose tissue (VAT), L4-5 
(cm2)b 
46.1 (34.4 - 61.7)c 79.0 (55.4 - 112.5) 0.02 
Hepatic fat fraction (HFF) (%) 3.78 (1.13)c 6.08 (5.04) 0.04 
Intramyocellular lipid (IMCL) (AU)d 0.030 (0.015) 0.030 (0.014) 0.87 
Data expressed as mean (SD) for normally distributed data 611 
adata expressed as median (IQR) for non-normally distributed data 612 
bgeometric mean (95% CI) for log transformed data 613 
csample size=20 614 
dsample size; BAM=18, WEM=22615 
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Table 2: Substrate kinetics before and after insulin adjustments during the basal state and the 616 
hyperinsulinaemic–euglycaemic clamp 617 












μmol /kg FFM min-1 
 
1.11 (0.71 – 2.72)a 1.55 (1.29 – 2.27)a 0.10 0.64 (0.52, 0.78)b 0.77 (0.63, 0.93)bd 0.17 
Adipose tissue insulin 
sensitivity index; ATIS 





12.16 x10-3   
(9.06 x10-3, 16.31 
x10-3)b 
0.40 10.2 x10-3  
(4.61 x10-3) 




μmol /kg FFM min-1 
13.60 (1.24) 13.74 (1.33) 0.72 4.37 (3.94 – 5.64)a 3.23 (2.71 – 6.14)ac 0.38 
Hepatic insulin sensitivity 
index; HISI 
(μmol /kg FFM min-1 · 
pmol/l)-1 
 
1.57 x10-3  
(6.61 x10-4) 
1.70 x10-3  
(7.18 x10-4) 
0.56 1.35 x10-3  
(9.23 – 16.32 x10-4) 
a 
1.68 x10-3  




μmol /kg FFM min-1 
- - - 51.14 (44.61 – 
60.16)a 





Glycerol and glucose isotope kinetics derived from the basal post absorptive state and during the hyperinsulinaemic–euglycaemic clamp. 618 
Glycerol Ra and Glucose Ga was derived from the low dose insulin phase (10 mU m−2 BSA min−1 ). Glucose Rd was derived during the high 619 
dose insulin phase (40 mU m−2 BSA min−1 ) infusion during the hyperinsulinaemic–euglycaemic clamp. Hepatic insulin sensitivity index (HISI) 620 
and peripheral insulin sensitivity index (PISI) are corrected for by insulin at the basal state and during the high dose insulin phase respectively.  621 
Data expressed as mean (SD) 622 
adata expressed as median (IQR) 623 
bgeometric mean (95% CI) 624 
csample size; 21 625 
dsample size; 22 626 
Ra = Rate of appearance 627 




(μmol /kg FFM min-1 )/ 
pmol/l 
 
- - - 9.71 x10-2   
(3.43 x10-2) 
10.78 x10-2 











Data presented using the Pearson correlation coefficients. Peripheral insulin sensitivity index was measured during the high dose insulin phase 635 
(40 mU m-2 BSA min-1), suppression of endogenous glucose production and whole body lipolysis was measured during the low dose insulin 636 
phase (10 mU m-2 BSA min-1). 637 
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Supplementary table 1: Associations between whole body insulin sensitivity and ectopic fat 638 
  VAT area (cm2) IHL (%) IMCL (AU) 
M; 
mg/kg FFM min-1 
Whole cohort r=-0.67, p<0.01 r=-0.61, p<0.01 r=-0.36, p=0.03 
BAM r=-0.46, p=0.06 r=-0.18, p=0.48 r=0.00, p=0.98 
WEM 
 
r=-0.80, p<0.01 r=-0.72, p<0.01 r=-0.52, p=0.01 
M/I; 
((mg/kg FFM min-1) / 
(pmol/l)) 
Whole cohort r=-0.63, p<0.01 r=-0.61, p<0.01 r=-0.40, p=0.01 
BAM r=-0.56, p=0.02 r=-0.34, p=0.17 r=-0.10, p=0.71 
WEM 
 
r=-0.78, p<0.01 r=-0.73, p<0.01 r=-0.54, p=0.01 
Correlation coefficients determined using Pearson’s correlation. VAT, IHL and IMCL were log transformed to improve normality. 639 
Abbreviations: BAM, Black West African men; IHL, intrahepatic lipid; IMCL, intramyocellular lipid; VAT, visceral adipose tissue; WEM, 640 




Supplementary figure 1: Hyperinsulinaemic–euglycaemic clamp time course 643 
644 
 645 
Data expressed as mean (SEM). Plasma glucose (A) and insulin (B) and concentrations 646 




Supplementary figure 2: Percentage change in glucose and glycerol kinetics during the 649 




(A) Suppression of whole body lipolysis during low dose insulin phase, presented as mean 654 
(SD) (B) Increase in peripheral glucose utilisation during high dose insulin phase, presented 655 
as mean (SD) (C) Suppression of endogenous glucose production during low dose insulin 656 
phase, presented as median (IQR). 657 
